Structure via PubChem · Public domain (PubChem)
temozolomide
Sign in to saveAlso known as TMZ, methazolastone, 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
Temozolomide, sold under the brand name Temodar among others, is an anticancer medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477861554
- Drug.image
- Temozolomide structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 160
- Drug.image2
- Temozolomide-3D-spacefill.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 160
- Drug.tradename
- Temodar, Temodal, Temcad, others
- Drug.MedlinePlus
- a601250
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Temozolomide
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- AX03
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C6H6N6O2
- Molecular weight
- 194.15 g/mol
- IUPAC name
- 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
- SMILES
- CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
- InChIKey
- BPEGJWRSRHCHSN-UHFFFAOYSA-N
- XLogP
- -1.1
- Polar surface area
- 106 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Research
12,869 papers- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.Lancet (London, England) · 2019
- Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.Biochimica et biophysica acta. Reviews on cancer · 2021
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.The Lancet. Oncology · 2012
- Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery.Naunyn-Schmiedeberg's archives of pharmacology · 2024
via PubMed
~11 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemical properties
- History
- Research
- References
- Further reading
- External links
Temozolomide, sold under the brand name Temodar among others, is an anticancer medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.
The most common side effects with temozolomide are nausea, vomiting, constipation, loss of appetite, alopecia (hair loss), headache, fatigue, convulsions (seizures), rash, neutropenia or lymphopenia (low white-blood-cell counts), and thrombocytopenia (low blood platelet counts). People receiving the solution for infusion may also have injection-site reactions, such as pain, irritation, itching, warmth, swelling and redness, as well as bruising.
Excerpted from Wikipedia’s “temozolomide” article, available under the CC BY-SA 4.0 licence.